DRTS Alpha Tau Medical Ltd

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2023

 

Commission File Number: 001-41316

 

 

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒       Form 40-F ☐

 

 

 

CONTENTS

 

On December 20, 2023, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau to Present at the 42^nd Annual J.P. Morgan Healthcare Conference.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

The information in this Report on Form 6-K, including in Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press release dated December 20, 2023.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Alpha Tau Medical Ltd.
Date: December 20, 2023	By:	/s/ Uzi Sofer
		Uzi Sofer
		Chief Executive Officer

 

 

3

Exhibit 99.1

 

Alpha Tau to Present at the 42^nd Annual J.P. Morgan Healthcare Conference

 

- The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well as robust long-term data analyzed across four clinical trials -

 

- The Company will also be featured at the Biotech Showcase™ occurring in parallel, and will host institutional investor meetings at both conferences -

 

JERUSALEM, December 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Chairman and CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the 42^nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.

 

A live webcast of the presentation will be available via a link located on the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://www.alphatau.com/events. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.

 

In addition, the Company also announced plans to present on Monday, January 8, 2024 at 11:30am PT at the Biotech Showcase occurring in parallel with the Healthcare Conference in San Francisco, and will host institutional investor meetings at the event.

 

42nd Annual J.P. Morgan Healthcare Conference:

 

Presentation Date/Time: Thursday, January 11, 2024, at 10:30 am PT / 1:30 pm ET
Location: Westin St. Francis San Francisco; California East room
Webcast: Link located on the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://www.alphatau.com/events

 

Biotech Showcase:

 

Presentation Date/Time: Monday, January 8, 2024 at 11:30am PT
Location: Hilton San Francisco Union Square in San Francisco; Yosemite A (Ballroom Level)
To schedule a meeting, investors can register on the Biotech Showcase: https://informaconnect.com/biotech-showcase/registration-options/.

 

About Alpha DaRT™

 

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

 

About Alpha Tau Medical Ltd.

 

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

 

Investor Relations Contact

 

IR@alphatau.com

 

 

 

 

---